Literature DB >> 19664366

An update on treatment and prevention strategies for Alzheimer's disease.

Judith Neugroschl1, Mary Sano.   

Abstract

With the aging of the population, the incidence and prevalence of Alzheimer's disease will grow, increasing the burden on individuals and society. While ameliorating symptoms, the currently available treatments approved by the US Food and Drug Administration do not halt progression or cure the illness. This article discusses recent data on treatment strategies targeting amyloid and tau pathology. Novel therapeutic strategies such as inhibitors of receptors for advanced glycation end products (RAGE), potential mitochondrial modification with Dimebon, anti-inflammatory approaches, and cholesterol-lowering agents are also reviewed. An update on results from pharmacologic and nonpharmacologic prevention trials is provided.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19664366      PMCID: PMC6485240          DOI: 10.1007/s11910-009-0054-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  64 in total

1.  Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels.

Authors:  N N Lermontova; A E Redkozubov; E F Shevtsova; T P Serkova; E G Kireeva; S O Bachurin
Journal:  Bull Exp Biol Med       Date:  2001-11       Impact factor: 0.804

2.  Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Authors:  E R Siemers; J F Quinn; J Kaye; M R Farlow; A Porsteinsson; P Tariot; P Zoulnouni; J E Galvin; D M Holtzman; D S Knopman; J Satterwhite; C Gonzales; R A Dean; P C May
Journal:  Neurology       Date:  2006-02-28       Impact factor: 9.910

3.  Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

Authors:  D L Sparks; D J Connor; M N Sabbagh; R B Petersen; J Lopez; P Browne
Journal:  Acta Neurol Scand Suppl       Date:  2006

4.  Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease.

Authors:  J P Spencer; J T Brown; J C Richardson; A D Medhurst; S S Sehmi; A R Calver; A D Randall
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

5.  Neuropathological diagnostic criteria for Alzheimer's disease.

Authors:  Shigeo Murayama; Yuko Saito
Journal:  Neuropathology       Date:  2004-09       Impact factor: 1.906

6.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Authors:  Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

7.  Mitochondria as a target for neurotoxins and neuroprotective agents.

Authors:  Sergey O Bachurin; Elena P Shevtsova; Elena G Kireeva; Gregory F Oxenkrug; Sergey O Sablin
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

8.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

Authors:  C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh
Journal:  Neurology       Date:  2007-04-25       Impact factor: 9.910

9.  Ginkgo biloba for prevention of dementia: a randomized controlled trial.

Authors:  Steven T DeKosky; Jeff D Williamson; Annette L Fitzpatrick; Richard A Kronmal; Diane G Ives; Judith A Saxton; Oscar L Lopez; Gregory Burke; Michelle C Carlson; Linda P Fried; Lewis H Kuller; John A Robbins; Russell P Tracy; Nancy F Woolard; Leslie Dunn; Beth E Snitz; Richard L Nahin; Curt D Furberg
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

10.  Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.

Authors:  Cynthia M Carlsson; Carey E Gleason; Timothy M Hess; Kimberly A Moreland; Hanna M Blazel; Rebecca L Koscik; Nathan T N Schreiber; Sterling C Johnson; Craig S Atwood; Luigi Puglielli; Bruce P Hermann; Patrick E McBride; James H Stein; Mark A Sager; Sanjay Asthana
Journal:  J Alzheimers Dis       Date:  2008-03       Impact factor: 4.472

View more
  17 in total

1.  Tarenflurbil in patients with mild Alzheimer's disease.

Authors:  Karen Marder
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

Review 2.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

3.  The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice.

Authors:  Angélica Maria Sabogal-Guáqueta; Juan Ignacio Muñoz-Manco; Jose R Ramírez-Pineda; Marisol Lamprea-Rodriguez; Edison Osorio; Gloria Patricia Cardona-Gómez
Journal:  Neuropharmacology       Date:  2015-02-07       Impact factor: 5.250

Review 4.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

5.  Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.

Authors:  Ozioma C Okonkwo; Michelle M Mielke; H Randall Griffith; Abhay R Moghekar; Richard J O'Brien; Leslie M Shaw; John Q Trojanowski; Marilyn S Albert
Journal:  Arch Neurol       Date:  2011-01

6.  Tritium-labeled (E,E)-2,5-bis(4'-hydroxy-3'-carboxystyryl)benzene as a probe for β-amyloid fibrils.

Authors:  Sergey V Matveev; Stefan Kwiatkowski; Vitaliy M Sviripa; Robert C Fazio; David S Watt; Harry LeVine
Journal:  Bioorg Med Chem Lett       Date:  2014-10-06       Impact factor: 2.823

7.  Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents.

Authors:  William Horton; Abha Sood; Swarada Peerannawar; Nandor Kugyela; Aditya Kulkarni; Rekha Tulsan; Chris D Tran; Jessica Soule; Harry LeVine; Béla Török; Marianna Török
Journal:  Bioorg Med Chem Lett       Date:  2016-11-24       Impact factor: 2.823

8.  Deep brain stimulation: a novel strategy for treating Alzheimer's disease.

Authors:  Constantine G Lyketsos; Steven D Targum; Jo Cara Pendergrass; Andres M Lozano
Journal:  Innov Clin Neurosci       Date:  2012-11

9.  Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up.

Authors:  Shanshan Li; Ozioma Okonkwo; Marilyn Albert; Mei-Cheng Wang
Journal:  Am J Alzheimers Dis (Columbia)       Date:  2013

10.  Are guidelines needed for the diagnosis and management of incipient Alzheimer's disease and mild cognitive impairment?

Authors:  Katie Palmer; Massimo Musicco; Carlo Caltagirone
Journal:  Int J Alzheimers Dis       Date:  2010-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.